Versor Investments LP Makes New $519,000 Investment in Lantheus Holdings, Inc. $LNTH

Versor Investments LP purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 7,800 shares of the medical equipment provider’s stock, valued at approximately $519,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Blue Trust Inc. raised its stake in Lantheus by 30.3% in the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 230 shares during the last quarter. United Community Bank boosted its stake in shares of Lantheus by 15.6% during the 3rd quarter. United Community Bank now owns 1,815 shares of the medical equipment provider’s stock worth $93,000 after purchasing an additional 245 shares during the last quarter. Farther Finance Advisors LLC grew its holdings in shares of Lantheus by 71.4% during the fourth quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 275 shares in the last quarter. Verdence Capital Advisors LLC grew its holdings in shares of Lantheus by 3.8% during the fourth quarter. Verdence Capital Advisors LLC now owns 8,455 shares of the medical equipment provider’s stock worth $563,000 after buying an additional 310 shares in the last quarter. Finally, Concurrent Investment Advisors LLC raised its position in shares of Lantheus by 10.3% in the third quarter. Concurrent Investment Advisors LLC now owns 3,936 shares of the medical equipment provider’s stock valued at $202,000 after buying an additional 366 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Lantheus Trading Up 0.2%

Shares of LNTH stock opened at $96.46 on Thursday. The firm’s 50-day simple moving average is $81.24 and its 200-day simple moving average is $69.94. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $98.27. The firm has a market cap of $6.28 billion, a P/E ratio of 23.24 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. Lantheus’s revenue was up 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 4.3 EPS for the current year.

Analysts Set New Price Targets

LNTH has been the topic of several recent analyst reports. Citizens Jmp upped their price objective on shares of Lantheus from $85.00 to $115.00 and gave the company a “market outperform” rating in a research note on Friday, May 8th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $110.00 target price on shares of Lantheus in a research note on Tuesday, March 17th. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a report on Friday, May 1st. William Blair restated an “outperform” rating on shares of Lantheus in a report on Tuesday, March 17th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $115.00 price objective (up from $98.00) on shares of Lantheus in a research report on Monday. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.71.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.